 Home > Medical News > Medicines Company News > CStone's KIT/PDGFRA mutant kinase inhibitor avatinib was approved in China

CStone's KIT/PDGFRA mutant kinase inhibitor avatinib was approved in China

 Last Update: 2021-05-03
 Source: Internet
 Author: User

Tags

specific

cocaine drug

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Today, China’s National Food and Drug Administration (NMPA) drug approval certificate pending information shows that the KIT and PDGFRA mutant kinase inhibitor avapritinib (previously used Chinese name: apotinib) declared by CStone Pharmaceuticals is already available China was approved.

It is reported that the approved indication for avatinib this time is: for the treatment of unresectable or metastatic gastrointestinal stromal tumor (GIST) adult patients with PDGFRA exon 18 mutation (including PDGFRA D842V mutation).

Avatinib is a highly specific KIT and PDGFRA mutant kinase inhibitor developed by Blueprint Medicines.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.